Skip to content

Optivista : I-SCAN OE for Optical Diagnosis of Small Colon Polyps

Optivista : I-SCAN OE for Optical Diagnosis of Small Colon Polyps

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03515343
Acronym
Optivista
Enrollment
411
Registered
2018-05-03
Start date
2018-03-09
Completion date
2019-03-31
Last updated
2021-07-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colo-rectal Cancer, Polyps of Colon

Keywords

Cancer prevention, Endoscopy, Gastroenterology

Brief summary

This prospective randomized clinical trial aims to evaluate the new Optivista system compared to the iScan for his optical diagnosis and interval agreement monitoring with pathology. The Participants will be randomized to be diagnosed by either Optivista or Pentax iScan, and all polyps detected during the procedure, their size, location and morphology will be recorded according to the Paris classification after which all polyps will be resected per standard practices and sent for histopathologic evaluation. Further optical assessments will be performed for all polyps of 1-10 mm in size (WASP, NICE, SANO and SIMPLE classification) after with an analysis of comparison between optical diagnosis and pathology results will be performed.

Detailed description

The benefit of colonoscopy screening is based on the detection and removal of polyps neoplastic. However, the vast majority of found polyps do not harbor any risk of non-cancer neoplastic. The resection evaluation and histopathology of these polyps are associated with costs while the contribution to cancer prevention is limited. A new technique (Pentax Optivista) based on visual diagnosis of polyps has been introduced to reduce the costs associated with over-screening, and seems to be more efficient than the Pentax iScan technique. This research project aims to evaluate the new Optivista system compared to the iScan for his optical biopsy performance and interval agreement monitoring with pathology. This is a prospective clinical trial for which participants are recruited directly from the colonoscopy clinic. The Participants will be randomized to be diagnosed by either Optivista or Pentax iScan. Endoscope withdrawal will be done in iScan 1 mode for patients randomized to iSan and in Optivista OE2 mode for patients randomized to Optivista. For all polyps detected during the procedure, their size, location and morphology will be recorded according to the Paris classification after which all polyps will be resected per standard practices and sent for histopathologic evaluation. Polyps that are between 1-10mm in size (diminutive and small polyps), there will be further assessed according to WASP, NICE, SANO and SIMPLE classifications using white light imaging and using an image-enhancing endoscopy technology that enhances visualisation of the polyp surface and vascular patterns. Concordance between optical diagnosis and pathology monitoring according to recommendations will be presented as proportions with a 95% CI. The features optical polyp diagnostic test for overall diminutive (1-5mm) polyps and by location in the colon (proximal, distal, colon and rectosigmoid segments) will be presented. For outcome measures secondary factors, including factors that may influence the optical diagnosis, proportional estimates with a 95% confidence interval (CI) will be presented. Concordance between strategies is examined using a marginal homogeneity test (Stuart-Maxwell test). For the comparison of proportions, a chi square test or a Fisher's exact two-sided test will be used, as appropriate.

Interventions

DIAGNOSTIC_TESTScreening colonoscopy according to resect-and-discard strategy

This strategy uses image enhancing techniques and optical diagnosis instead of histopathology assessment with 2 Pentax optical imaging systems (either Optivista or iScan).

Sponsors

Pentax Medical
CollaboratorINDUSTRY
Centre hospitalier de l'Université de Montréal (CHUM)
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
45 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* Signed informed consent * Aged 45 to 80 years * Indication for full colonoscopy

Exclusion criteria

* Known inflammatory bowel disease * Active colitis * Coagulopathy * Familial polyposis syndrome * Poor general health defined as an ASA class \> 3 * Emergency colonoscopies

Design outcomes

Primary

MeasureTime frameDescription
Concordance of Optical diagnosis with the pathology based reference standard12 monthsThe Optical diagnosis of polyps using Optivista or iScan will be compared with the pathology based reference standard.
Rate of polyps detected of both of the technologies (Optivista and iScan) for Optical diagnosis12 months

Secondary

MeasureTime frameDescription
Concordance of biopsies and SIMPLE classification12 monthsVerification of concordance (yes/no) between histopathological results (biopsies) and SIMPLE classification for polyps up to 10mm in size in conjunction with iScan and Optivista (depending on randomization).
Concordance of biopsies and SANO classification12 monthsVerification of concordance (yes/no) between histopathological results (biopsies) and SANO classification for polyps up to 10mm in size in conjunction with iScan and Optivista (depending on randomization).
Negative predictive value of rectosigmoid neoplastic polyps.12 monthsSecondary outcomes and data collection include test characteristics, particularly the negative predictive value of rectosigmoid neoplastic polyps.
Surveillance recommendation following the colonoscopy12 monthsThe proportion of patients for whom an immediate surveillance recommendation following the colonoscopy can be directly provided for each approach and how often histopathology polyp examination would have been avoided when using each strategy will be examined.
Evaluate Polyp-Based Resect and Discard model12 monthsSurveillance interval agreement of the PBRD strategy compared with pathology-based management according to the 2020 USMSTF guidelines.
Concordance of biopsies and NICE classification12 monthsVerification of concordance (yes/no) between histopathological results (biopsies) and NICE classification for polyps up to 10mm in size in conjunction with iScan and Optivista (depending on randomization).
Concordance of biopsies with WASP classification12 monthsVerification of concordance (yes/no) between histopathological results (biopsies) and WASP classification for polyps up to 10mm in size in conjunction with iScan and Optivista (depending on randomization).

Countries

Canada

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 25, 2026